Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573351 · ClinicalTrials.gov registry record · Phase 3
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 398
- Enrollment target
NCT01573351: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT01573351 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 398 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01573351, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 398 participants
- Enrollment target
Study Summary
The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) \< Limit of quantitation (LOQ) at post-treatment Week 12.
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG Asunaprevir
- DRUG Peg-interferon Alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
What the finished NCT01573351 record still lists
NCT01573351 is an interventional study that assigns participants to a tested intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01573351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01573351 about?
NCT01573351 is a clinical study titled "Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)". The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) \< Limit of quantitation (LOQ) at post-treatment Week 12.
What is the current status of trial NCT01573351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 398 participants. The study started on 2012-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01573351?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Asunaprevir (DRUG), Peg-interferon Alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01573351?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01573351's enrollment target sits among peer trials
398 963rd of 2000 higher than 1,037 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia